Keyphrases
Meta-analysis
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Chemotherapy Agents
100%
Third Generation
100%
Platinum-based
100%
Risk Difference
85%
Confidence Interval
71%
Monotherapy
71%
1-year Survival
42%
Non-small Cell Lung Cancer (NSCLC)
28%
Best Supportive Care
28%
Inclusion Criteria
14%
Randomized Trial
14%
Gemcitabine
14%
Randomized Controlled Trial
14%
Am(III)
14%
Tumor Response
14%
Paclitaxel
14%
Exclusion Criteria
14%
Irinotecan
14%
MEDLINE
14%
Tumor Survival
14%
Subset Analysis
14%
Docetaxel
14%
High Response Rate
14%
Risk Response
14%
Equivalency
14%
Platinum Doublets
14%
Vinorelbine
14%
Three-arm Trial
14%
Medicine and Dentistry
Meta-Analysis
100%
Non Small Cell Lung Cancer
100%
Attributable Risk
100%
Chemotherapy Agent
100%
Monotherapy
83%
Survival Rate
33%
Supportive Care
33%
Neoplasm
16%
Arm
16%
Randomized Controlled Trial
16%
Paclitaxel
16%
Irinotecan
16%
Gemcitabine
16%
Docetaxel
16%
Treatment of Non-Small Cell Lung Cancer
16%
Vinorelbine
16%